这家总部位于北卡罗来纳州罗利市的企业，在截至2025年9月30日的12个月内实现营收10亿美元。公司 计划在纳斯达克交易所上市，股票代码为LMRI，并已于2025年6月12日提交了保密招股书。本次IPO的 联席账簿管理人包括巴克莱、摩根大通、杰富瑞、德意志银行、富国证券、Leerink Partners、William Blair、Capital One Securities、Fifth Third Securities、Raymond James及PNC Capital Markets。目前尚未披 露发行价格条款。 智通财经APP获悉，门诊影像诊断服务提供商Lumexa Imaging Holdings(LMRI.US)于周一向美国证券交 易委员会(SEC)提交上市申请，预计通过此次首次公开募股(IPO)筹集最多2亿美元资金。 作为全美性门诊诊断影像服务提供商，Lumexa Imaging通过全资运营及与医疗系统合资合作的模式，在 13个州运营着184家诊疗中心。公司提供包括磁共振(MRI)、计算机断层扫描(CT)、正电子发射断层显像 (PET)、X光、超声及乳房X光检查在内的各类先进及常规影像检查服务。该 ...

据知情人士透露，中国生物科技公司阿格纳生物制药有限公司已选定在香港进行首次公开募股(IPO)的 银行，融资规模可达数亿美元。知情人士透露，这家由金杏资本支持的公司正与美国银行、中金公司、 Jefferies Financial Group Inc.和摩根大通合作。他们表示，该公司已秘密提交IPO申请，但补充说规模和 时间等细节仍在商讨中。 ...

Core Viewpoint - Central Bancompany (CBCY.US) announced its initial public offering (IPO) terms, planning to raise $400 million by issuing 17.8 million shares at a price range of $21 to $24 per share, aiming for a market capitalization of $5.4 billion [1][2]. Group 1: Company Overview - Central Bancompany is a super community bank with 156 full-service branches across 17 metropolitan statistical areas (MSAs), primarily focused in Missouri and expanding into Kansas, Oklahoma, Colorado, and Florida [1]. - The company was established in 1902 and reported total assets of $19.2 billion, net loans of $11.3 billion, deposits of $14.8 billion, and total equity of $3.3 billion as of September 30, 2025 [1][2]. Group 2: Financial Performance - For the 12 months ending September 30, 2025, Central Bancompany generated revenue of $956 million [2]. Group 3: IPO Details - The IPO will be listed on the Nasdaq under the ticker symbol "CBC," with Morgan Stanley, Keefe, Bruyette & Woods, Bank of America Securities, Piper Sandler, and Stephens Inc. serving as joint book-running managers for the offering [2].

股东信息显示，宇树科技由王兴兴、汉海信息技术(上海)有限公司、宁波红杉科盛股权投资合伙企业(有 限合伙)等共同持股。 变更记录显示，今年5月，宇树科技正式名称由"杭州宇树科技有限公司"变更为"杭州宇树科技股份有限 公司"。 10月23日，据天眼查App显示，宇树科技完成更名。"杭州宇树科技股份有限公司"企业名称变更为"宇 树科技股份有限公司"。同时，王兴兴由执行公司事务的董事变更为董事长。 王兴兴 资料图 图源：新华社 宇树科技成立于2016年8月，法定代表人为王兴兴，注册资本约3.64亿人民币，经营范围包括智能机器 人的研发、智能机器人销售、工业机器人制造等。 今年7月8日，中信证券与宇树科技通过公开发行辅导监管系统提交了辅导备案登记材料；7月18日，中 国证监会网上办事服务平台对辅导备案报告进行了公示。 今年9月2日，宇树科技在社交平台上发布声明称，"公司正积极推进首次公开募股(IPO)的筹备工作"， 并表示"预计将于10月至12月间向证券交易所提交上市申请文件，届时相关运营数据将正式披露。" 10月21日，据报道，宇树科技IPO辅导机构中信证券近日提交了"辅导工作进展情况报告(第一期)"。 报告透露，本 ...

与此同时，连接和数据传输设备供应商上海剑桥科技股份限公司（CIG）上海的融资目标为46.2亿港 元，人工智能应用解决方案供应商深信科技的融资目标为7.1亿港元。高端茶叶销售商八马茶的融资目 标为4.5亿港元。 香港证券交易所下周将迎来重磅交易日，包括中国最大的建筑机械制造商三一重工在内的四只股票即将 首次亮相，这将使香港今年重新成为全球顶级融资场所。 在10月28日上市的四只股票中，已在上海上市的三一重工计划融资金额最高，计划通过两地主要上市发 行5.8042亿股股票，融资额高达123.6亿港元（15.9亿美元）。 约10%的股份将用于香港公开发行，其余股份将用于国际发行。 首次公开募股(IPO)是公司发展历程中的一个变革性里程碑！作为知名的美国上市咨询辅导机构，宏业 金融集团致力为大中华地区（大陆、香港、台湾）及泛亚太地区公司提供上市辅导咨询服务，帮助他们 做好 IPO 的成功准备。宏业金融以专业、靠谱、值得信赖的服务理念和精神，从始至终指导拟上市公 司，对其进行战略定位，以在更短时间内实现其在美上市融资目标！ 宏业金融声明：宏业金融集团（简称"宏业金融"）为开曼群岛合法注册公司，是国内知名的境外IPO上 ...

Barentsz Capital成立于2023年，在截至2025年4月30日的12个月内实现营收100万美元。公司计划在纳斯 达克证券交易所挂牌上市，股票代码为BRKK，国泰证券将担任此次发行的独家账簿管理人。 据介绍，Barentsz Capital专注于为企业家和企业提供管理咨询与科技咨询服务，在战略规划与落地执行 层面提供全方位解决方案。公司主要通过咨询项目创收，截至2025年4月30日已服务约21家客户。 智通财经APP获悉，总部位于中国香港的管理与科技咨询公司Barentsz Capital(BRKK.US)于周二公布了 其首次公开募股(IPO)的发行条款。该公司计划以每股4至6美元的价格发行130万股，募集600万美元资 金。按发行价区间中值计算，其市值将达到1.06亿美元。 ...

Core Viewpoint - Medline, a medical supplies manufacturer, is considering submitting its IPO application by the end of October, potentially becoming the largest IPO in the U.S. for the year if successful [1][2] Group 1: IPO Details - Medline aims to raise approximately $5 billion through the IPO, with backing from major investors including Blackstone, Carlyle Group, and Hellman & Friedman [1] - The company is headquartered in Northfield, Illinois, and had previously filed for an IPO in a "confidential" manner last December [1] - Goldman Sachs and Morgan Stanley are the lead underwriters for the IPO, with a potential valuation of up to $50 billion [1][2] Group 2: Market Context - The current U.S. stock market is near historical highs, with low volatility, and has raised $32 billion in IPOs this year, which is below the average for the same period before the pandemic [2] - If Medline successfully raises $5 billion, it would surpass the $1.75 billion raised by Venture Global in January, making it the largest IPO of the year [2] Group 3: Company Overview - Medline produces a range of medical supplies for hospitals and healthcare facilities, including gloves, surgical gowns, and examination tables, employing over 43,000 people globally [2] - The projected net sales for Medline in 2024 are approximately $25.5 billion [2] - The company was involved in a $34 billion leveraged buyout by private equity firms, which was one of the largest private equity transactions in history [2]

Group 1 - The Federal Reserve's interest rate cut has cleared the path for private companies to enter the U.S. IPO market, with many companies expected to file for IPOs in the coming weeks [1][3] - Companies like Neptune Insurance Holdings Inc. and the parent company of the University of Phoenix have submitted applications to U.S. regulators and may begin roadshows soon [1][3] - The current market conditions, including the U.S. stock market nearing historical highs and low volatility, are favorable for IPOs, leading to expectations of more companies conducting roadshows [1][2] Group 2 - As of mid-September, 14 companies have raised $7 billion through U.S. IPOs, marking the highest level for this period since 2020 [2] - If the market remains strong, the number of notable transactions in October may exceed those in September [2] - The beginning of the Federal Reserve's easing cycle is expected to create opportunities for companies seeking to go public, with a need for timely applications to avoid delays until 2026 [3] Group 3 - The fall IPO window has opened, with the number of IPOs reaching or exceeding $250 million, the highest level since October 2021 [3] - Recent IPO performance has been mixed, with some companies like StubHub Holdings Inc. and Gemini Space Station Inc. seeing stock prices fall below their IPO prices, while others like Figure Technology Solutions Inc. and Black Rock Coffee Bar Inc. have seen significant gains [4] - The performance of newly listed companies is crucial for encouraging investor interest in future IPOs, with recent trends prompting a reassessment of market conditions [4]

Group 1 - Cohesity is preparing for a potential IPO in 2026, aiming for a valuation comparable to its competitor Rubrik, which has a market cap of $17 billion [1] - The company abandoned its earlier IPO plans to merge with Veritas' data protection division, completing the merger in December 2024, which positioned Cohesity as the largest data protection software provider with a 19% market share [1] - Following the merger, Cohesity's valuation exceeded $7 billion [1] Group 2 - The CEO expressed a desire for Cohesity to become a major player in the industry before going public, indicating that the company is currently a "small fish" compared to competitors like Rubrik and Commvault [1] - Cohesity's fiscal year ends in August, suggesting that the company may not be ready for an IPO until the fall of 2026, contingent on maintaining strong business momentum [1] - The CEO believes that if Cohesity can demonstrate performance metrics similar to Rubrik, its valuation could be "comparable or even higher" [1]

总部位于香港的钢筋预制服务提供商屈铁臣(科技)有限公司(BENN.US)上周五向美国证券交易委员会提 交申请，计划通过首次公开募股(IPO)融资至多600万美元。这家总部位于中国香港的公司计划以每股4 至6美元的价格区间发行130万股股票，融资600万美元。按照拟议区间的中间价计算，屈铁臣的市值将 达到1.25亿美元。 屈铁臣通过其运营子公司为钢筋(螺纹钢)提供定制的场外切割弯曲服务。该公司运营着香港土木工程拓 展署批准的六个钢筋预制场之一，主要客户是香港建筑署(HKBO)注册的总承包商以及香港各类建筑和 基础设施项目的分包商。屈铁臣为公共和私营部门项目提供钢筋弯曲和切割服务。 这家总部位于中国香港的公司成立于2021年，计划在纳斯达克上市，股票代码为BENN。Revere Securities是此次交易的唯一账簿管理人。 ...